Why Most Clinical AI Insights Arrive Too Late to Matter

Key takeaways:  

• One of the most underdiscussed problems in clinical artificial intelligence (AI) isn’t the quality of the insights it produces. It’s where, when, and how those insights reach the people making decisions. 
• When AI-driven analyses live in separate siloed systems and take days or weeks to retrieve, mostly due to operational inefficiencies, they fail to influence decisions in real time. High-quality outputs get downgraded to background reference material. 
• The clinical operations teams seeing the largest gains from AI have closed this gap by embedding intelligence directly into centralized workflows where decisions happen. A recent example shows what that shift looks like in practice and what it produces. 

The previous five posts in this blog series have built a case about clinical AI: that performance is determined by data quality, that the four pillars of AI-ready data give you a structured way to evaluate where gaps exist, that the results when those pillars are met are substantial, and that the data foundation generalizes globally when the underlying network is built for it. 

This post addresses a different question. Even when the data foundation is right, even when the AI is producing high-quality insights, why are so many clinical operations teams not seeing the productivity gains the technology promised? 

The answer is rarely about the insights themselves. It’s almost always about how and where they are delivered. 

The Days-to-Seconds Gap

In most clinical operations environments today, getting an AI-driven analysis means making a request. Maybe to an internal team, maybe to a vendor, maybe through a separate platform that requires its own login, training, and learning curve. The request gets queued. A specialist runs the analysis. Results come back in days, sometimes weeks.

By the time those results arrive, the decision they are supposed to inform has often already been made. The protocol has been finalized. The site list has been locked. The recruitment plan has been distributed. What was supposed to be decision-shaping intelligence becomes after-the-fact validation, or worse, evidence that the decision was suboptimal. 

This is what workflow friction looks like in clinical operations. It’s not a productivity story about saving 15 minutes here or there. It’s a story about whether AI insights reach the moment of decision, or whether they arrive too late to influence the decisions they were generated to support. 

The teams getting the most value out of clinical AI today have figured something out. The technology that produces the insight matters. So does the path the insight takes from production to use. When that path is days or weeks long, even the best AI underperforms. When it’s seconds, the same AI delivers fundamentally different results. 

What Embedded Intelligence Actually Looks Like

A pharma organization working with TriNetX wanted to bring AI-powered RWD insights directly into the place where clinical study protocols are authored, rather than maintaining the typical separation between protocol design tools and the analytics platforms that inform them. 

Before the change, the workflow was familiar to anyone in the field. Protocol authors would identify a question (about cohort size, about eligibility criteria viability, about realistic site distribution). They would route the question through internal feasibility teams or external vendors and then wait. Days later, sometimes longer, the analysis would come back, often after a follow-up question or two had emerged in the meantime. 

After the change, those same questions could be answered during the authoring session itself. A protocol author considering a specific eligibility criterion could query a connected RWD environment, see the resulting cohort size in real time, adjust the criterion, and see the new cohort size, all without leaving the protocol document. A question about geographic feasibility could be answered against current data while the relevant section was being written. A comparative analysis between two potential cohort definitions could happen in the same session as the decision about which definition to use. 

The shift was not about a new algorithm. The underlying AI was substantially the same. What changed was where the intelligence lived and how directly it connected to the work being done. 

The result was a compression of the entire feasibility-and-design phase. Rather than waiting on analyses, protocol authors were iterating against them in real time. Decisions that previously required separate work sessions, separate teams, and separate tools could happen in the flow of normal protocol authoring. The output wasn’t just faster protocols. It was protocols informed by more analytical iterations, because each iteration cost minutes instead of days. 

Why This Matters Beyond Speed

Time-to-insight is the easiest part of this story to measure. It’s not the most important part. 

When AI insights take days to retrieve, the cost isn’t just the days. It’s the questions that don’t get asked because the cost of asking is too high. Every clin ops leader knows the experience of having a question, calculating that getting an answer would take three days, and deciding to proceed with the existing assumption rather than wait. Multiply that decision across hundreds of questions per study, across dozens of studies per portfolio, and the cumulative cost is enormous, even though it never appears on any specific timeline. 

Embedded intelligence changes the calculus. When the cost of asking a question drops to seconds, more questions get asked. Assumptions that would have gone unexamined get tested. Edge cases that would have been ignored get explored. The quality of decisions improves not because the AI is smarter but because more of the decisions get to benefit from it. 

This is the gap most clinical operations teams underestimate when they evaluate AI investments. The technology that produces good insights is necessary. The infrastructure that puts those insights in front of the right person at the right moment is what determines whether the investment pays off. 

The Operational Implication

For clinical operations leaders evaluating where to invest next, the implication is concrete. The question isn’t only “can this AI produce useful insights?” It’s also “where do those insights need to live, and how directly can they connect to the workflows that need them?” 

A vendor that produces high-quality outputs but requires those outputs to be requested, retrieved, and translated into the actual decision context is offering a partial solution. A vendor whose intelligence is embeddable, queryable through standard interfaces, and accessible during the moment of decision is offering something different. As clinical AI capabilities mature, deployment architecture is becoming an increasingly important differentiator. 

About Asad Basir 

Asad serves as Vice President of Product at TriNetX, where he leads the development of the company’s product roadmap. He is focused on translating customer needs and market insights into solutions that help life sciences and healthcare organizations unlock the value of real-world data and advance clinical research across the drug development lifecycle.